Having a decreased Hb was shown to be an independent risk factor both for requiring a perioperative blood transfusion and for the volume of transfusion. The very modest increase in Hb achieved by the costly and time-consuming preoperative anemia optimization program, however, may not be justified when the use of intraoperative TXA led to drastic reductions in both transfusions and transfusion volumes.
The statements and opinions expressed in COVID-19 Curbside Consults are based on experience and the available literature as of the date posted. While we try to regularly update this content, any offered recommendations cannot be substituted for the clinical judgment of clinicians caring for individual patients.
Background
Blood transfusions though life‐saving are not entirely benign. They are the most overused procedure in the hospital and have been under scrutiny by the ‘Choosing Wisely campaign’. The strict adoption of restrictive transfusion guidelines could improve patient outcomes while reducing cost.
Objectives
In this study, we evaluate adherence to restrictive transfusion guidelines, along with hospital mortality and length of stay (LOS) in transfusion events with a pre‐transfusion haemoglobin (Hb) ≥7 g/dl. Additionally, we evaluated associated costs accrued due to unnecessary transfusions.
Methods
We conducted a retrospective observational study in a 64‐bed medical intensive care unit (MICU) of an academic medical centre involving all adult patients (N = 957) requiring packed red blood cell transfusion between January 2015 and December 2015.
Results
In total, 3140 units were transfused with a mean pre‐transfusion Hb of 6.75 ± 0.86 g/dl. Nine hundred forty‐four (30%) transfusion events occurred with a pre‐transfusion Hb ≥7 g/dl, and 385 (12.3%) of these occurred in patients without hypotension, tachycardia, use of vasopressors, or coronary artery disease. Forgoing them could have led to a savings of approximately 0.3 million dollars. Transfusion events with pre‐transfusion Hb ≥7 g/dl were associated with an increased mortality in patients with acute blood loss (odds ratio [OR] 2.08, 95% confidence interval [CI] 1.11–3.88; p = 0.02) and LOS in patients with chronic blood loss (β1.8.26, 95% CI 4.09–12.43; p < 0.01).
Conclusion
A subset of anaemic patients in the MICU still receive red blood cell transfusions against restrictive guidelines offering hospitals the potential for effective intervention that has both economic and clinical implications.
Blood transfusion therapy in the 21st century continues to present limitations regarding efficacy and risks. Blood management partners optimal blood transfusion therapy with anemia management that incorporates nonblood strategies and techniques. A planned approach to anemia prevention, identification, and treatment can reduce the need for blood transfusion and improve patient outcomes. The use of pharmaceutical agents and tools to minimize blood loss also leads to blood transfusion reduction. Nurses play an integral role in affecting the use of alternatives to blood transfusion. Through assessment, communication, and an understanding of blood management strategies, nurses are patients' front-line innovators in promoting best practices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.